Lisata Therapeutics Appoints Jeffrey Farrow to Board of Directors
Lisata Therapeutics, Inc. (LSTA) expanded its board of directors to eight members with the appointment of Jeffrey Farrow, effective Oct. 13, 2026. Farrow will also serve on the company's Audit Committee. Shares of the biotechnology company declined 4.17% to $1.035 following the announcement.
Farrow brings experience as a biopharmaceutical chief financial officer with a track record in mergers and acquisitions. His addition aims to enhance corporate governance and financial oversight as the company advances its Phase 2b clinical programs following its acquisition of Marea.
Moving forward, investors will focus on upcoming clinical trial readouts, potential financing decisions, and business development initiatives influenced by the updated board leadership.
Key points
- Jeffrey Farrow joined the Lisata Therapeutics board of directors effective Oct. 13, 2026, and will serve on the Audit Committee.
- The appointment expands the company's board of directors to eight members.
- Farrow is an experienced biopharmaceutical CFO with expertise in mergers and acquisitions.
- The governance change comes as Lisata advances its Phase 2b clinical programs following its acquisition of Marea.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Who did Lisata Therapeutics add to its board of directors?
Lisata Therapeutics appointed Jeffrey Farrow to its board of directors, effective Oct. 13, 2026, expanding the board to eight members.
What role will Jeffrey Farrow play at Lisata Therapeutics?
Jeffrey Farrow will serve on the board of directors and the Audit Committee, contributing biopharmaceutical CFO experience and M&A expertise.
How did Lisata Therapeutics stock react to the news?
Lisata Therapeutics stock fell 4.17% to $1.035 following the announcement.